Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Multicenter, Randomized, 48 Week, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate Efficacy and Safety of CER-001 on Vessel Wall Area in Patients With Genetically Defined Familial Primary Hypoalphalipoproteinemia

NCT02697136 is registered in ClinicalTrials.gov with Cerenis Therapeutics, SA as lead sponsor.

NCT NCT02697136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02697136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Multicenter, Randomized, 48 Week, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate Efficacy and Safety of CER-001 on Vessel Wall Area in Patients With Genetically Defined Familial Primary Hypoalphalipoproteinemia
Lead sponsor
Cerenis Therapeutics, SA
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2015
Completion date
December 21, 2018
Enrollment
30 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

familial hypoalphalipoproteinemia